Ribonucleic Acid Interference (RNAi) Technology Industry Poised for Rapid Growth, Forecast to Touch $9.19 Billion by 2030 at 15.6% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the ribonucleic acid interference (rnai) technology market from 2026–2035 with trusted insights from The Business Research Company
What size range is anticipated for the Ribonucleic Acid Interference (RNAi) Technology Market from 2026 to 2030?
The ribonucleic acid interference (rnai) technology market size has witnessed significant expansion recently. It is anticipated to increase from $4.43 billion in 2025 to $5.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.9%. The past growth can be linked to advancements in molecular biology research, early clinical successes of rnai therapeutics, the expansion of academic gene research programs, the availability of robust screening libraries, and the development of biotech innovation ecosystems.
The ribonucleic acid interference (rnai) technology market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $9.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.6%. Factors contributing to this growth over the projected period include the increasing market availability of rnai-based medications, growing financial commitments to treatments for rare diseases, advancements in nanoparticle delivery systems, expanding collaborations within the pharmaceutical sector, and greater regulatory approval for gene-silencing therapies. Key developments foreseen during the forecast timeframe encompass the wider embrace of gene silencing approaches, increased utilization of sirna-based therapeutic platforms, the deepening incorporation of rnai into personalized medicine, a broadening of treatments for specific genetic disorders, and improved optimization of delivery systems.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30371&type=smp
What Drivers Are Affecting Demand In The Ribonucleic Acid Interference (RNAi) Technology Market?
The ribonucleic acid interference (RNAi) technology market is anticipated to expand due to the escalating need for targeted therapeutics. These therapies are defined as interventions that precisely address and suppress molecular irregularities in conditions like cancer, aiming to enhance treatment accuracy and reduce damage to healthy cells. The heightened emphasis on targeted treatments largely stems from progress in precision medicine, which facilitates bespoke and more efficacious therapies tailored to individual genetic characteristics. Ribonucleic Acid Interference (RNAi) Technology boosts the requirement for targeted therapeutics through its capacity for exact gene silencing in managing genetic and rare ailments. This technology facilitates the creation of exceptionally specific and potent treatments, thereby fostering innovation within personalized medicine. An illustrative example includes data from December 2024, where the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, reported that the Food and Drug Administration (FDA) granted approval to 6 gene therapy products in 2023, an increase from 5 approvals in 2022. Consequently, the growing need for targeted therapeutics is propelling the expansion of the ribonucleic acid interference (RNAi) technology market.
Which Segments Are Gaining Traction In The Ribonucleic Acid Interference (RNAi) Technology Market?
The ribonucleic acid interference (rnai) technology market covered in this report is segmented –
1) By Product: Micro Ribonucleic Acid (miRNA), Small Interfering Ribonucleic Acid (siRNA), Other Products
2) By Delivery Method: Viral Vectors, Nanoparticles, Chemical Modifications, Physical Methods
3) By Application: Therapeutics, Drug Discovery, Agriculture, Diagnostics
4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs) And Contract Manufacturing Organizations (CMOs)
Subsegments:
1) By Micro Ribonucleic Acid (miRNA): Micro Ribonucleic Acid Mimics, Micro Ribonucleic Acid Inhibitors, Micro Ribonucleic Acid Expression Vectors, Micro Ribonucleic Acid Profiling And Quantification Kits
2) By Small Interfering Ribonucleic Acid (siRNA): Small Interfering Ribonucleic Acid Synthetic Duplexes, Small Interfering Ribonucleic Acid Dicer Substrate Molecules, Small Interfering Ribonucleic Acid Self Delivering Conjugates, Small Interfering Ribonucleic Acid N Acetylgalactosamine Conjugates
3) By Other Products: Short Hairpin Ribonucleic Acid Expression Constructs, Ribonucleic Acid Interference Screening Libraries, Ribonucleic Acid Interference Transfection Reagents, Micro Ribonucleic Acid And Small Interfering Ribonucleic Acid Research Kits
How Are Emerging Trends Affecting The Progression Of The Ribonucleic Acid Interference (RNAi) Technology Market?
Leading firms within the ribonucleic acid interference (RNAi) technology market are prioritizing platform integration, including strategic funding and support, to optimize the development, delivery, and market introduction of RNA interference (RNAi) therapeutics, thereby fostering a continuous flow of numerous programs across various disease domains. This strategic funding and support involves obtaining investments and resources from venture capital firms, industry collaborators, and other involved parties to speed up the research, development, and market release of RNA interference (RNAi) therapeutics. As an illustration, in October 2024, City Therapeutics Inc., a US-based biopharmaceutical company, secured $135 million through Series A financing, spearheaded by ARCH Venture Partners and joined by other prominent life sciences investors, with the aim of advancing RNA interference (RNAi)-based medicine. This capital infusion is intended to further the development of RNAi-based medicine by utilizing its proprietary lipid nanoparticle (LNP) delivery platform, which is specifically engineered to precisely target tissues outside the liver. The platform seeks to address a significant past constraint in the domain, thereby facilitating the creation of treatments for a broader spectrum of genetic conditions.
Who Are The Primary Competitors In The Global Ribonucleic Acid Interference (RNAi) Technology Market?
Major companies operating in the ribonucleic acid interference (rnai) technology market are F. Hoffmann-La Roche AG, Merck KGaA, Novartis AG, Thermo Fisher Scientific Inc., Danaher Corporation, Revvity Inc., QIAGEN N.V., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., GenScript Biotech Corporation, Promega Corporation, Arrowhead Pharmaceuticals Inc., Silence Therapeutics plc, Creative Biolabs Inc., Bioneer Corporation, Genevant Sciences Ltd., Gradalis Inc., Altogen Labs LLC, Sirnaomics Inc., Altogen Biosystems Inc.
Access The Complete Report For Deeper Market Insights:
Which Global Regions Are Shaping The Competitive Landscape Of The Ribonucleic Acid Interference (RNAi) Technology Market?
North America was the largest region in the ribonucleic acid interference (RNAi) technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid interference (rnai) technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Ribonucleic Acid Interference (RNAi) Technology Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=30371&type=smp
Browse Through More Reports Similar to the Global Ribonucleic Acid Interference (RNAi) Technology Market 2026, By The Business Research Company
Ribonucleic Acid Rna Sequencing Market Report 2026
Nucleic Acid Isolation And Purification Market Report 2026
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
